Literature DB >> 6661376

Pharmacokinetics of brotizolam in renal failure.

J Evers, E Renner, W D Bechtel.   

Abstract

Kinetics of brotizolam (0.25 mg) were studied in patients with different degrees of renal failure after single and repeated oral ingestion. Serum levels were analysed by radio-immunoassay. Patients were divided into three groups according to their renal function, i.e. creatinine clearance values of 45-80, 15-45, or less than 15 ml/min. The mean elimination half-life was 6.9-8.15 h, with a considerable variation of the peak concentration and elimination half-life in slight to moderate renal failure. There was no delay in elimination in severe renal failure and there was no drug accumulation. No dose adjustment is necessary for brotizolam in renal failure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661376      PMCID: PMC1428209          DOI: 10.1111/j.1365-2125.1983.tb02305.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Clinical pharmacokinetics of hypnotic benzodiazepines: a summary.

Authors:  D D Breimer; R Jochemsen
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

2.  Drug therapy in renal failure: dosing guidelines for adults. Part II: sedatives, hypnotics, and tranquilizers; cardiovascular, antihypertensive, and diuretic agents; miscellaneous agents.

Authors:  W M Bennett; R S Muther; R A Parker; P Feig; G Morrison; T A Golper; I Singer
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

3.  Pharmacokinetics and metabolism of brotizolam in humans.

Authors:  W D Bechtel
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

  3 in total
  1 in total

Review 1.  Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic.

Authors:  M S Langley; S P Clissold
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.